These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 8308316)

  • 1. Measles, mumps and rubella immunisation in children at risk of infection with human immunodeficiency virus.
    Molyneaux PJ; Mok JY; Burns SM; Yap PL
    J Infect; 1993 Nov; 27(3):251-3. PubMed ID: 8308316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A search for persistent measles, mumps, and rubella vaccine virus in children with human immunodeficiency virus type 1 infection.
    Frenkel LM; Nielsen K; Garakian A; Cherry JD
    Arch Pediatr Adolesc Med; 1994 Jan; 148(1):57-60. PubMed ID: 8143011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The immunological efficacy of the combined vaccine Trimovax intended for the prevention of measles, mumps and rubella].
    Samoĭlovich EO; Kapustik LA; Fel'dman EV; Ermolovich MA; Svirchevskaia EIu; Titov LP; Zakharenko DF; Belova EIu; Chernovetskiĭ MA; Korostik TS
    Zh Mikrobiol Epidemiol Immunobiol; 1998; (4):36-40. PubMed ID: 9783398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Age-related seroprevalence of measles, mumps and rubella antibodies in 1996].
    Zäch K; Nicoara C; Germann D; Matter L
    Schweiz Med Wochenschr; 1998 Apr; 128(17):649-57. PubMed ID: 9622837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Seroconversion rates to combined measles-mumps-rubella-varicella vaccine of children with upper respiratory tract infection.
    Dennehy PH; Saracen CL; Peter G
    Pediatrics; 1994 Oct; 94(4 Pt 1):514-6. PubMed ID: 7936862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune response after primary and re-vaccination with different combined vaccines against measles, mumps, rubella.
    Tischer A; Gerike E
    Vaccine; 2000 Jan; 18(14):1382-92. PubMed ID: 10618536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decline in rates of seropositivity for measles, mumps, and rubella antibodies among previously immunized children treated for acute leukemia.
    Feldman S; Andrew M; Norris M; McIntyre B; Iyer R
    Clin Infect Dis; 1998 Aug; 27(2):388-90. PubMed ID: 9709893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serologic response to measles-mumps-rubella vaccine among children with upper respiratory tract infection.
    Cilla G; Peña B; Marimón JM; Pérez-Trallero E
    Vaccine; 1996 Apr; 14(6):492-4. PubMed ID: 8782345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of a combined measles-mumps-rubella-chickenpox vaccine.
    Just M; Berger R; Just V
    Dev Biol Stand; 1986; 65():85-8. PubMed ID: 3030863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody persistence after primary measles-mumps-rubella vaccine and response to a second dose given at four to six vs. eleven to thirteen years.
    Johnson CE; Kumar ML; Whitwell JK; Staehle BO; Rome LP; Dinakar C; Hurni W; Nalin DR
    Pediatr Infect Dis J; 1996 Aug; 15(8):687-92. PubMed ID: 8858673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Measles, mumps, and rubella antibodies in vaccinated Baltimore children.
    King JC; Lichenstein R; Feigelman S; Luna C; Permutt TJ; Patel J
    Am J Dis Child; 1993 May; 147(5):558-60. PubMed ID: 8488803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The combination measles, mumps, rubella and varicella vaccine in healthy children.
    Arbeter AM; Baker L; Starr SE; Plotkin SA
    Dev Biol Stand; 1986; 65():89-93. PubMed ID: 3030864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunity to and immunization against measles, rubella and mumps in patients after autologous bone marrow transplantation.
    Pauksen K; Duraj V; Ljungman P; Sjölin J; Oberg G; Lönnerholm G; Fridell E; Smedmyr B; Simonsson B
    Bone Marrow Transplant; 1992 Jun; 9(6):427-32. PubMed ID: 1628126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody response to measles-mumps-rubella vaccine of children with mild illness at the time of vaccination.
    King GE; Markowitz LE; Heath J; Redd SC; Coleman S; Bellini WJ; Sievert A
    JAMA; 1996 Mar; 275(9):704-7. PubMed ID: 8594268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Measles, mumps, rubella antibody surveillance: pilot study in Grampian, Scotland.
    Narayan KM; Moffat MA
    Health Bull (Edinb); 1992 Jan; 50(1):47-53. PubMed ID: 1612895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of a two-dose measles, mumps, and rubella vaccination schedule in a cohort of college athletes.
    Coté TR; Sivertson D; Horan JM; Lindegren ML; Dwyer DM
    Public Health Rep; 1993; 108(4):431-5. PubMed ID: 8341775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measles and rubella antibody response after measles-mumps-rubella vaccination in children with afebrile upper respiratory tract infection.
    Ratnam S; West R; Gadag V
    J Pediatr; 1995 Sep; 127(3):432-4. PubMed ID: 7658276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes of the immunological patterns against measles, mumps and rubella. A vaccination programme studied 3 to 7 years after the introduction of a two-dose schedule.
    Christenson B; Böttiger M
    Vaccine; 1991 May; 9(5):326-9. PubMed ID: 1872016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response to measles, mumps and rubella vaccine in paediatric bone marrow transplant recipients.
    King SM; Saunders EF; Petric M; Gold R
    Bone Marrow Transplant; 1996 Apr; 17(4):633-6. PubMed ID: 8722367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of vaccination of marrow transplant recipients with a live attenuated measles, mumps, and rubella vaccine.
    Ljungman P; Fridell E; Lönnqvist B; Bolme P; Böttiger M; Gahrton G; Linde A; Ringdén O; Wahren B
    J Infect Dis; 1989 Apr; 159(4):610-5. PubMed ID: 2647859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.